The Relationship of Statins Usage and Bone Mineral Density in Postmenopausal Women

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Anatomical Sciences and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Student of Medicine, School of Medicine AND Student Research committee, Isfahan University of Medical Sciences, Isfahan, Iran

4 Department of Biomedical Engineering, University of Birmingham, United Kingdom

Abstract

Background: Osteoporosis is a common disease that is most prevalent in postmenopausal women. Statins are lipid lowering agents and their role in increasing bone mineral density has been reported in many studies. We conducted this study to evaluate the relationship of statin consumption and bone density in postmenopausal women.Methods: 350 patients with a mean age of 62.03 ± 6.12 years (range: 43-82 years) were enrolled in this study. Patients underwent dual-energy x-ray absorptiometry (DXA) measurements at hip, lumbar spines (L2, L3, and L4), greater trochanter and femur neck. Statin usage by patients was recorded. Results [showed as T-score and bone mineral density (BMD) in g/cm2] were compared between the patients who were or were not taking statins. The patients were divided in three groups according to T-score (normal, osteopenic and osteoporotic). Then, the data were analyzed using chi-square (for qualitative variables), t (for quantitative variables) and the Mann-Whitney tests via SPSS18 software.Findings: Significant differences were found between the two groups in mean BMD of lumbar spines (L2, L3, and L4), greater trochanter and femur neck. Statin users had higher BMD. No significant difference in BMD of hip was observed. Frequency distribution of patients with osteoporosis, osteopenia, and normal density of lumbar spines (L2, L3, and L4) and femur neck in two groups was found to be significantly different.Conclusion: Statins showed to have positive impact on bone density in lumbar spines (L2, L3, and L4), greater trochanter and femur neck, but in BMD of hip no significant difference was observed. According to the results of this study, statins can have an important role in prevention of osteoporosis.

Keywords

References

  1. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285(13): 1711-8.
  2. Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol 2000; 86(3): 257-62.
  3. Knatterud GL, Rosenberg Y, Campeau L, Geller NL, Hunninghake DB, Forman SA, et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. Circulation 2000; 102(2): 157-65.
  4. Jordan KM, Cooper C. Epidemiology of osteoporosis. Best Pract Res Clin Rheumatol 2002; 16(5): 795-806.
  5. Gonyeau MJ. Statins and osteoporosis: a clinical review. Pharmacotherapy 2005; 25(2): 228-43.
  6. Christenson ES, Jiang X, Kagan R, Schnatz P. Osteoporosis management in post-menopausal women. Minerva Ginecol 2012; 64(3): 181-94.
  7. Hejazi J, Mohtadinia J, Kolahi S, Ebrahimi-Mamaghani M. Nutritional status among postmenopausal osteoporotic women in North West of Iran. Asia Pac J Clin Nutr 2009; 18(1): 48-53.
  8. Tsartsalis AN, Dokos C, Kaiafa GD, Tsartsalis DN, Kattamis A, Hatzitolios AI, et al. Statins, bone formation and osteoporosis: hope or hype? Hormones (Athens ) 2012; 11(2): 126-39.
  9. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000; 355(9222): 2185-8.
  10. Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 2000; 85(3): 1137-42.
  11. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral density in postmenopausal women. Lancet 2000; 355(9222): 2218-9.
  12. Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakano T, Fujita T. Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am J Med 2001; 110(7): 584-7.
  13. Lima CE, Calixto JC, Anbinder AL. Influence of the association between simvastatin and demineralized bovine bone matrix on bone repair in rats. Braz Oral Res 2011; 25(1): 42-8.
  14. van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA 2001; 285(14): 1850-5.
  15. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286(5446): 1946-9.
  16. Chuengsamarn S, Rattanamongkoulgul S, Suwanwalaikorn S, Wattanasirichaigoon S, Kaufman L. Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia. Bone 2010; 46(4): 1011-5.
  17. Cruz AC, Gruber BL. Statins and osteoporosis: can these lipid-lowering drugs also bolster bones? Cleve Clin J Med 2002; 69(4): 277-8, 280-2, 287-8.
  18. Patil S, Holt G, Raby N, McLellan AR, Smith K, O'Kane S, et al. Prospective, double blind, randomized, controlled trial of simvastatin in human fracture healing. J Orthop Res 2009; 27(3): 281-5.
  19. Bone HG, Kiel DP, Lindsay RS, Lewiecki EM, Bolognese MA, Leary ET, et al. Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. J Clin Endocrinol Metab 2007; 92(12): 4671-7.
  20. Sirola J, Sirola J, Honkanen R, Kroger H, Jurvelin JS, Maenpaa P, et al. Relation of statin use and bone loss: a prospective population-based cohort study in early postmenopausal women. Osteoporos Int 2002; 13(7): 537-41.
  21. Toh S, Hernandez-Diaz S. Statins and fracture risk. A systematic review. Pharmacoepidemiol Drug Saf 2007; 16(6): 627-40.
  22. Rejnmark L, Olsen ML, Johnsen SP, Vestergaard P, Sorensen HT, Mosekilde L. Hip fracture risk in statin users--a population-based Danish case-control study. Osteoporos Int 2004; 15(6): 452-8.
  23. Helin-Salmivaara A, Korhonen MJ, Lehenkari P, Junnila SY, Neuvonen PJ, Ruokoniemi P, et al. Statins and hip fracture prevention--a population based cohort study in women. PLoS One 2012; 7(10): e48095.
  24. Pedersen TR, Kjekshus J. Statin drugs and the risk of fracture. 4S Study Group. JAMA 2000; 284(15): 1921-2.
  25. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 2001; 357(9255): 509-12.
Journal of Isfahan Medical School
Volume 32, Issue 281 - Serial Number 281
March and April 2014
Pages 493-502

Files

History

  • Receive Date: 23 November 2013
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics